• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    伦

    伦敦大学学院女王广场神经学研究所

    UCL Queen Square Institute of Neurology
    4,658论文总数
    39.3万引用总数

    The UCL Queen Square Institute of Neurology is an institute within the Faculty of Brain Sciences of University College London (UCL) and is located in London, United Kingdom. Together with the National Hospital for Neurology and Neurosurgery, an adjacent facility with which it cooperates closely, the institute forms a major centre for teaching, training and research in neurology and allied clinical and basic neurosciences.The institute has a staff of around 710 and 500 graduate students, an annual turnover of £81million and occupies around 12,000 sq m of laboratory and office space. Four of the 12 most highly cited authors in neuroscience and behaviour in the world are currently based at the institute. The institute conducts research into a wide range of neurological diseases, including movement disorders, multiple sclerosis, epilepsy, brain cancer, stroke and brain injury, muscle and nerve disorders, cognitive dysfunction and dementia. It forms a key part of UCL Neuroscience.

    论文量&引用量时间轴

    机构学者

    论文(4658)

    年份
    起
    –
    止
    排序
    1Performance of the 2024 McDonald Criteria in Patients under Evaluation for Suspected Multiple Sclerosis
    Wallace J Brownlee, Davide Maccarrone, Riccardo Nistri, Charmaine Yam,Heather Wilson,Sarah Wright,Kshitij Mankad,Cheryl Hemingway, Alan J Thompson,Yael Hacohen, Ahmed T Toosy,Olga Ciccarelli

    Background and Objectives The 2024 McDonald criteria provide new recommendations for multiple sclerosis (MS) diagnosis, but validation of the criteria is lacking. We wanted to investigate the application and performance of the 2024 McDonald criteria in patients with suspected MS seen in routine clinical practice. Methods We retrospectively identified patients referred with clinical and/or radiologic suspicion for MS between January and December 2024. All patients had a minimum diagnostic evaluation with brain and spinal cord MRI. The 2017 McDonald criteria were applied prospectively, and the 2024 McDonald criteria were applied retrospectively after the initial diagnostic workup and at last follow-up. We investigated (1) the number of patients diagnosed with MS using the 2017 McDonald criteria or the 2024 McDonald criteria, and (2) the diagnostic performance of the 2024 McDonald criteria when applied during the initial diagnostic workup, with an MS diagnosis using the 2017 McDonald criteria as the reference-standard. Results In 347 patients (mean age 39.4 years, 66% female) with suspected MS followed up for mean 15.3 (range 8-20) months, 73 (21%) had alternative disorders and were excluded. After applying the 2024 McDonald criteria in the remaining 274 patients, more patients were diagnosed with MS after the initial diagnostic workup (220 vs 172, p < 0.01), and at follow-up (237 vs 204, p < 0.01), compared with the 2017 McDonald criteria, and fewer patients were diagnosed with clinically or radiologically isolated syndrome. The median time to diagnosis was 40 vs 84 days (p < 0.01), respectively. After initial diagnostic workup, the 2024 McDonald criteria demonstrated high sensitivity (92.6%, 95% CI 88.1%-95.8%) and accuracy (83.6%, 95% CI 78.7%-87.8%), for an MS diagnosis using 2017 McDonald criteria at last follow-up, but moderate specificity (57.8%, 95% CI 45.4%-69.4%). The increased rate of MS diagnosis and the diagnostic performance of the revised criteria was similar in children (<18 years) and older adults (>50 years). Discussion Use of the 2024 McDonald allows for earlier MS diagnosis, but also more frequent diagnosis including in patients with radiologically isolated syndrome. The revised criteria have similar performance across the lifespan. Limitations include the lack of data on central vein sign and kappa free light chains, and missing optic nerve assessment in some patients.

    2026Neurology(2026)引用:6
    引用
    AI阅读
    加入学术空间
    2The Promise of GLP-1 Receptor Agonists for Neurodegenerative Diseases
    Dilan Athauda, Nigel H Greig,Wassilios G Meissner,Thomas Foltynie,Sonia Gandhi

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs), established therapies for type 2 diabetes and obesity, are increasingly recognized fortheir potential in neurodegenerative diseases. Preclinical studies across diverse neurodegenerative conditions consistently demonstrate neuroprotective effects of GLP-1RAs, including reduced protein aggregation, enhanced autophagy, improved mitochondrial function, suppression of neuroinflammation, and preservation of synaptic integrity. Epidemiological analyses further suggest reduced incidence of dementia, Parkinson disease, and multiple sclerosis among long-term GLP-1RA users. Early human trials provide signals of target engagement, such as preserved cerebral glucose metabolism, altered inflammatory biomarkers, and slowed brain atrophy, although clinical outcomes to date remain mixed and trials in rarer disorders are sparse. Translation is constrained by uncertainty around optimal molecule choice, CNS penetrance, tolerability, adherence, and heterogeneity of response. Furthermore, next-generation dual and triple agonists may offer enhanced efficacy but remain untested in neurodegeneration. Conceptually, GLP-1RAs share pleiotropic effects with exercise - one of the few interventions with proven disease-modifying potential - by enhancing insulin signaling, stabilizing mitochondria, reducing inflammation, and promoting synaptic plasticity. This overlap highlights their promise as "pharmacological analogues of exercise," and underscores the need for biomarker-driven, disease-specific trials to establish whether GLP-1RAs can deliver durable disease modification across the spectrum of neurodegenerative diseases.

    2026The Journal of clinical investigation(2026)引用:5
    引用
    AI阅读
    加入学术空间
    3New Evidence on the Clinical, Genetic, and Biochemical Bases of GBA1-Parkinson's Disease: Prospects for Treatment.
    Elisa Menozzi,Marco Toffoli,Michela Deleidi,Donato A Di Monte,Fabio Blandini,Dimitri Krainc,Ellen Sidransky, Anthony H V Schapira

    GBA1 variants are common genetic risk factors for Parkinson's disease and also for dementia with Lewy bodies. New evidence highlights the relationship between the different GBA1 variants and their associated clinical presentation and disease progression, although penetrance is low and the majority of carriers do not develop a synucleinopathy. The clinical profile of GBA1-associated Parkinson's disease is characterised by a faster rate of progression with more severe cognitive and autonomic dysfunction than idiopathic Parkinson's disease, particularly in those carrying severe pathogenic variants. The mechanisms involved in phenotypic conversion and disease progression in carriers of GBA1 variants are being elucidated, and this knowledge could be translated into clinically relevant biomarker profiles. GBA1 has become a target for intervention for both GBA1-associated Parkinson's disease and idiopathic Parkinson's disease, with therapeutic strategies aiming to prevent or slow disease progression via pharmacological chaperones, enzymatic allosteric activators, metabolic interventions, and modulation of gene expression.

    2026The Lancet Neurology(2026)引用:4
    引用
    AI阅读
    加入学术空间
    4Dorsal Prefrontal Cortex Drives Perseverative Behavior in Mice
    A Lebedeva, Y Wang, L Funnell, B Terry, Y J Oh,K Miller,K D Harris

    Perseveration - repeating one action when others would generate larger rewards - is a common behavior, but neither its purpose nor neuronal mechanisms are understood. Here we demonstrate a neural correlate and causal role of dorsal prefrontal cortex, specifically anterior secondary motor cortex (MOs) in perseveration in mice performing a dynamic reward learning task. An auditory go cue signaled mice to turn a wheel either left or right, with the reward probability of each action switching in blocks. Mice perseverated, gaining suboptimal reward, but were faster when making repeated choices. Neuropixels recordings found neurons whose activity correlated with perseveration and predicted rapid reaction times, almost exclusively in anterior MOs. Optogenetically inhibiting this region during the choice period reduced perseveration and slowed reactions. In contrast, inactivating medial prefrontal cortex at choice time had no effect, but inactivating it after reward delivery impaired learning. In this task, therefore, anterior MOs reflects a perseverative decision variable, and is necessary for mediating the effect of this decision variable on choice and reaction time.

    2026Nature communications(2026)引用:3
    引用
    AI阅读
    加入学术空间
    5Author Correction: the Solve-RD Solvathons As a Pan-European Interdisciplinary Collaboration to Diagnose Patients with Rare Disease
    Vicente A. Yépez, German Demidov,Kornelia Ellwanger,Steven Laurie, Rebeka Luknárová, Midhuna Immaculate Joseph Maran,Thomas Hentrich,Lydia Sagath,Bart van der Sanden, Galuh Astuti,Kornelia Neveling, Laura Batlle-Masó,

    Despite advances in genomic diagnostics, the majority of individuals with rare diseases remain without a confirmed genetic diagnosis. The rapid emergence of advanced omics technologies, such as long-read genome sequencing, optical genome mapping and multiomic profiling, has improved diagnostic yield but also substantially increased analytical and interpretational complexity. Addressing this complexity requires systematic multidisciplinary collaboration, as recently demonstrated by targeted diagnostic workshops. Here, we highlight the experience of the Solve-RD consortium, a pan-European initiative, in implementing four structured workshops, termed 'Solvathons', as a regular and effective component of its operational workflow. We provide actionable insights, best practices and lessons learned for successful data integration, expert training and scalable collaborative diagnostics within large research consortia.

    2026Nature Genetics(2026)引用:3
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 4658 篇论文

    合作机构(100)

    伦敦大学学院合作论文 612
    卢旺天主教大学合作论文 294
    国家神经病学和神经外科医院合作论文 267
    牛津大学合作论文 196
    剑桥大学合作论文 172
    国王大学合作论文 115
    纽卡斯尔大学 (澳大利亚)合作论文 107
    多伦多大学合作论文 99
    温纳贝戈医学中心合作论文 95
    伦敦大学学院大奥蒙德街儿童健康研究所合作论文 94

    机构统计